Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM(®): results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

BACKGROUND: Risperidone ISM(®) is a newly developed long-acting injectable (LAI) treatment for schizophrenia in adults. In the absence of head-to-head comparisons with other similar antipsychotics, the objective of this study was to generate indirect evidence of some aspects of the safety and tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez, Pedro, Álamo, Cecilio, Almendros, Marcos, Schlueter, Max, Tasoulas, Anastasios, Martínez, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474682/
https://www.ncbi.nlm.nih.gov/pubmed/37660132
http://dx.doi.org/10.1186/s12991-023-00464-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474682/
https://www.ncbi.nlm.nih.gov/pubmed/37660132
http://dx.doi.org/10.1186/s12991-023-00464-z

Ejemplares similares